The Motley Fool

Royal Bank of Scotland Group plc isn’t the only new stock Neil Woodford has bought

Neil Woodford has been highly active in buying and selling stocks during 2017. Indeed, it’s many a long year since his funds have undergone such a dramatic shift. Old favourites, such as GlaxoSmithKline and British American Tobacco, have been sold to help fund a major move into UK domestic cyclical stocks. And this is also where much of the £553m raised for the new Income Focus fund he launched this year has gone.

Banking on Britain

Woodford’s shift has been “designed to capture a contrarian opportunity that has emerged in domestic cyclical companies where valuations are too low and future growth expectations far too modest.”

5G is here – and shares of this ‘sleeping giant’ could be a great way for you to potentially profit!

According to one leading industry firm, the 5G boom could create a global industry worth US$12.3 TRILLION out of thin air…

And if you click here we’ll show you something that could be key to unlocking 5G’s full potential...

Banking is central to Woodford’s thesis about growth expectations. Up until this year, he maintained that the reason banks weren’t lending was simply because they didn’t have enough capital. He now believes they do and reckons they’re well placed to increase both lending and dividends for shareholders.

Pariah no more

Woodford has built up a big stake in Lloyds this year but revealed just a few days ago that he’s also been buying shares in Royal Bank of Scotland (LSE: RBS) and Barclays. The Scottish bank remains a pariah for a lot of investors but Woodford sees bright prospects, due to many of the reasons discussed recently by my Foolish colleague Rupert Hargreaves.

At a current price of 275p, RBS trades on a cheap forecast 2018 price-to-earnings (P/E) ratio of 10.6, with City analysts also expecting a 3.3% dividend yield. Personally, I’m not convinced that the time is ripe to invest in the still-70%-state-owned bank. However, confidence is on the rise judging by only four brokers currently rating the stock a ‘sell’ compared with 11 this time last year.

Strong industry fundamentals

Housebuilders are another of Woodford’s major plays on the UK domestic economy. FTSE 100 giants Taylor Wimpey and Barratt Developments feature prominently but there’s a host of others, including mid-cap Bovis Homes (LSE: BVS), which released a trading update today.

On the broad backdrop for housebuilding, Bovis said: “The demand for new homes continues to be robust across all our regions and customer interest remains good. The industry fundamentals are strong given the Government’s housing policy, in particular Help to Buy, the low interest rate environment, and the competitive mortgage market.”

House call

On Bovis’s own performance, management reported “strong sales,” “a high level of customer satisfaction” and that “initiatives to simplify and streamline our operating structure to reduce costs and make us more agile, are progressing well.”

As a result, the board said it’s confident of delivering on profit expectations this year and “a significant improvement in profits for FY 2018.” At a current share price of 1,120p, the forecast 2018 P/E is 12.4, while dividend forecasts imply a whopping yield of 8.4%.

Of course, Woodford’s big bet on banks, housebuilders and other domestic stocks rests to a large degree on a sanguine view of Brexit. He and his team see “considerable grounds for optimism that the long-term outcomes for the UK economy will be far better than the alarmed consensus would suggest.”

5G is here – and shares of this ‘sleeping giant’ could be a great way for you to potentially profit!

According to one leading industry firm, the 5G boom could create a global industry worth US $12.3 TRILLION out of thin air…

And if you click here, we’ll show you something that could be key to unlocking 5G’s full potential...

It’s just ONE innovation from a little-known US company that has quietly spent years preparing for this exact moment…

But you need to get in before the crowd catches onto this ‘sleeping giant’.

Click here to learn more.

G A Chester has no position in any of the shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. The Motley Fool UK has recommended Barclays. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Our 6 'Best Buys Now' Shares

The renowned analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.

So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we're offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our 'no quibbles' 30-day subscription fee refund guarantee.

Simply enter your email address below to discover how you can take advantage of this.

I would like to receive emails from you about product information and offers from The Fool and its business partners. Each of these emails will provide a link to unsubscribe from future emails. More information about how The Fool collects, stores, and handles personal data is available in its Privacy Statement.